On Wednesday, shares of Moderna, Inc. (MRNA.US) climbed higher, rising more than 6.7% to $29.17 at the time of reporting.

The stock movement came after the Centers for Disease Control and Prevention (CDC) released its latest adult and pediatric immunization schedule, marking the first time COVID vaccines have been classified under an "individualized decision-making" framework. The updated guidelines also recommend that young children receive chickenpox vaccines separately rather than in combination with measles, mumps, and rubella vaccines.

Acting CDC Director and Deputy Secretary of Health and Human Services Jim O'Neill stated that the new policy "brings informed consent back to medical practice." He noted that the 2022 universal vaccination recommendations had limited opportunities for physicians and patients to discuss vaccine risks and benefits.

The new guidelines emphasize that among individuals under 65 years of age, only those at high risk experience greater benefits from COVID vaccination. Low-risk individuals are encouraged to make vaccination decisions in consultation with their healthcare providers.